Webinar
Depot buprenorphine has been a game-changing treatment for opioid dependency and has been met with great enthusiasm and acceptability by consumers and clinicians alike. This study explores what it is like to receive depot buprenorphine and to understand why some people decide to stop this treatment.
Dr Clay is a postdoctoral research fellow at the National Drug & Alcohol Research Centre, University of New South Wales.